11 results
Primary Objectives-To evaluate if mitochondrial dysfunction can be induced in healthy, middle aged subjects, through the use of simvastatin, and whether it can be reversed by oral ubiquinol supplementation. -To validate the techniques NIRS, PpIX-…
Primary objective is to investigate the percentage of patients with k-ras mutant advanced or metastatic colorectal cancer free from progression and alive after 12.5 weeks after the first dose of cetuximab (i.e., 14 weeks after the scan at baseline…
The overall objectives of the iSPOT-D trial are to use standardised genetic-brain-cognitionprotocols to:1. Identify markers of MDD as a diagnostic group and its subtypes2. Identify markers which change with acute (8 weeks) drug treatment in MDD3.…
The aim of this study is to investigate the influence of statin therapy on DDAVP mediated release of VWF and F VIII. We aim to investigate this by measuring F VIII and VWF levels by means of a prolonged DDAVP test prior and after 6 weeks of statin…
To compare the effectiveness of the tocolytic agents Nifedipine (a calcium channel blocking agent) versus Atosiban (an oxytocin receptor antagonist) in the improvement of neonatal outcome in women with threatened preterm labour (25-34 weeks…
The purpose of this clinical pilot study is to generate quantitative evidence that the oral administration of 80 mg Simvastatin per day, three weeks before surgery and one week thereafter, will have a significant effect on fibrinolytic activity…
Determine effect of asprin and simvastatin on platelet and monocyte gene expression in vivo.
To assess the efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with natalizumab or ocrelizumab for at least six months.
are sildenafil, metformin and simvastatin effective in stimulation of ADH independent urine concentration in man?
The aim of this study is to assess the safety and tolerability of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis.
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF.